Publication | Closed Access

Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome

Hematological MalignancyPtk787/zk 222584MedicineAcute Myeloid LeukemiaReceptor Tyrosine KinaseHematologyPharmacotherapyPhase 1PharmacologyCell BiologyCell SignalingMyeloid Neoplasia